APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hospital-Acquired Pneumonia (HAP) Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Growth and Trends Forecast to 2032

22 December 2025104 pages

Choose your research edition.

Industry ResearchHospital-Acquired Pneumonia (HAP) Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital-Acquired Pneumonia (HAP) Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hospital-Acquired Pneumonia (HAP) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs include Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Novartis, Merck, Mylan, Pfizer, AstraZeneca, Theravance Biopharma and The Medicines Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hospital-Acquired Pneumonia (HAP) Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hospital-Acquired Pneumonia (HAP) Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hospital-Acquired Pneumonia (HAP) Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hospital-Acquired Pneumonia (HAP) Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hospital-Acquired Pneumonia (HAP) Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hospital-Acquired Pneumonia (HAP) Drugs Market by Company

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Novartis

Merck

Mylan

Pfizer

AstraZeneca

Theravance Biopharma

The Medicines Company

Shinogi

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Type

Antiviral

Antibacterial

Antifungal

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Application

Hospitals

Clinics

Others

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Pneumonia (HAP) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Pneumonia (HAP) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Pneumonia (HAP) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hospital-Acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hospital-Acquired Pneumonia (HAP) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Antiviral Table 2. Major Company of Antibacterial Table 3. Major Company of Antifungal Table 4. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2021-2026) & (US$/unit) Table 10. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2027-2032) & (k units) Table 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2027-2032) & (US$/unit) Table 15. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 16. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 18. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 22. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends Table 26. Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers Table 27. Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges Table 28. Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints Table 29. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Company (2021-2026) & (k units) Table 32. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Company (2021-2026) Table 33. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Price by Company (2021-2026) & (US$/unit) Table 34. Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Hospital-Acquired Pneumonia (HAP) Drugs Major Company Production Sites and Headquarters Table 36. Global Hospital-Acquired Pneumonia (HAP) Drugs Company, Product Type & Application Table 37. Global Hospital-Acquired Pneumonia (HAP) Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Hospital-Acquired Pneumonia (HAP) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2026) & (k units) Table 42. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2027-2032) & (k units) Table 47. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 53. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2021-2026) & (US$/unit) Table 57. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2027-2032) & (k units) Table 58. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2027-2032) & (US$/unit) Table 62. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 63. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 65. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 69. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Teva Pharmaceutical Industries Company Information Table 73. Teva Pharmaceutical Industries Business Overview Table 74. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 76. Teva Pharmaceutical Industries Recent Development Table 77. Sun Pharmaceutical Industries Company Information Table 78. Sun Pharmaceutical Industries Business Overview Table 79. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 81. Sun Pharmaceutical Industries Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 86. Novartis Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 91. Merck Recent Development Table 92. Mylan Company Information Table 93. Mylan Business Overview Table 94. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 96. Mylan Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 101. Pfizer Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Theravance Biopharma Company Information Table 108. Theravance Biopharma Business Overview Table 109. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 111. Theravance Biopharma Recent Development Table 112. The Medicines Company Company Information Table 113. The Medicines Company Business Overview Table 114. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 116. The Medicines Company Recent Development Table 117. Shinogi Company Information Table 118. Shinogi Business Overview Table 119. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 121. Shinogi Recent Development Table 122. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 123. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 124. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2026) Table 125. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032) & (k units) Table 126. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Country (2027-2032) Table 127. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 129. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country (2021-2026) Table 130. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Country (2027-2032) Table 132. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 133. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 134. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2026) Table 135. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032) & (k units) Table 136. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Country (2027-2032) Table 137. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 139. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country (2021-2026) Table 140. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 144. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2026) Table 145. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032) & (k units) Table 146. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 149. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country (2021-2026) Table 150. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Country (2027-2032) Table 152. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 153. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 154. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2026) Table 155. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032) & (k units) Table 156. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Country (2027-2032) Table 157. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 159. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country (2021-2026) Table 160. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 164. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2026) Table 165. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032) & (k units) Table 166. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 169. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country (2021-2026) Table 170. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Country (2027-2032) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List Table 175. Hospital-Acquired Pneumonia (HAP) Drugs Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. Hospital-Acquired Pneumonia (HAP) Drugs Image Figure 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (2021-2032) & (k units) Figure 5. Antiviral Image Figure 6. Global Antiviral Sales YoY Growth (2021-2032) & (k units) Figure 7. Antibacterial Image Figure 8. Global Antibacterial Sales YoY Growth (2021-2032) & (k units) Figure 9. Antifungal Image Figure 10. Global Antifungal Sales YoY Growth (2021-2032) & (k units) Figure 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Hospital-Acquired Pneumonia (HAP) Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 27. Clinics Image Figure 28. Global Clinics Sales YoY Growth (2021-2032) & (k units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Novartis
  • Merck
  • Mylan
  • Pfizer
  • AstraZeneca
  • Theravance Biopharma
  • The Medicines Company
  • Shinogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hospital-Acquired Pneumonia (HAP) Drugs Market by Type
  6. 1.3.1 Antiviral
  7. 1.3.2 Antibacterial
  8. 1.3.3 Antifungal
  9. 1.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Type
  10. 1.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends
  2. 2.2 Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers
  3. 2.3 Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges
  4. 2.4 Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Hospital-Acquired Pneumonia (HAP) Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Hospital-Acquired Pneumonia (HAP) Drugs Price (2021-2026)
  4. 3.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Hospital-Acquired Pneumonia (HAP) Drugs Company, Product Type & Application
  7. 3.7 Global Hospital-Acquired Pneumonia (HAP) Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hospital-Acquired Pneumonia (HAP) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hospital-Acquired Pneumonia (HAP) Drugs Tier 1, Tier 2, and Tier 3
4 Hospital-Acquired Pneumonia (HAP) Drugs Regional Status and Outlook
  1. 4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Historic Market Size by Region
  3. 4.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hospital-Acquired Pneumonia (HAP) Drugs by Application
  1. 5.1 Hospital-Acquired Pneumonia (HAP) Drugs Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Application
  6. 5.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries
  2. 6.1.1 Teva Pharmaceutical Industries Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 6.2 Sun Pharmaceutical Industries
  8. 6.2.1 Sun Pharmaceutical Industries Company Information
  9. 6.2.2 Sun Pharmaceutical Industries Business Overview
  10. 6.2.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  12. 6.2.5 Sun Pharmaceutical Industries Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Mylan
  26. 6.5.1 Mylan Company Information
  27. 6.5.2 Mylan Business Overview
  28. 6.5.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  30. 6.5.5 Mylan Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 AstraZeneca
  38. 6.7.1 AstraZeneca Company Information
  39. 6.7.2 AstraZeneca Business Overview
  40. 6.7.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  42. 6.7.5 AstraZeneca Recent Developments
  43. 6.8 Theravance Biopharma
  44. 6.8.1 Theravance Biopharma Company Information
  45. 6.8.2 Theravance Biopharma Business Overview
  46. 6.8.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  48. 6.8.5 Theravance Biopharma Recent Developments
  49. 6.9 The Medicines Company
  50. 6.9.1 The Medicines Company Company Information
  51. 6.9.2 The Medicines Company Business Overview
  52. 6.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  54. 6.9.5 The Medicines Company Recent Developments
  55. 6.10 Shinogi
  56. 6.10.1 Shinogi Company Information
  57. 6.10.2 Shinogi Business Overview
  58. 6.10.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  60. 6.10.5 Shinogi Recent Developments
7 North America by Country
  1. 7.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
  2. 7.1.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country
  6. 7.2.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
  2. 8.1.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country
  6. 8.2.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
  2. 10.1.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country
  6. 10.2.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Analysis
  2. 12.1.1 Hospital-Acquired Pneumonia (HAP) Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process
  7. 12.2 Hospital-Acquired Pneumonia (HAP) Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Distributors
  10. 12.2.3 Hospital-Acquired Pneumonia (HAP) Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst